EN
|
SE
Contact us
Careers
About
About BioInvent
Immuno-oncology
Business focus
Board of directors
Management team
Scientific advisory board
Career
Pipeline
Clinical pipeline
BI-1206 / BI-1808
Haematological cancers
Pre-clinical pipeline
TAMs
Tregs
Technology
F.I.R.S.T™
n-CoDeR
Intellectual property
Manufacturing
Partners
Investors
Share price
Financial reports
Presentations
Corporate governance
Subscribe
Media
Press releases
Events
Scientific publications
Image bank
About
About BioInvent
Immuno-oncology
Business focus
Board of directors
Management team
Scientific advisory board
Career
Pipeline
Clinical pipeline
BI-1206 / BI-1808
Haematological cancers
Pre-clinical pipeline
TAMs
Tregs
Technology
F.I.R.S.T™
n-CoDeR
Intellectual property
Manufacturing
Partners
Investors
Share price
Financial reports
Presentations
Corporate governance
Subscribe
Media
Press releases
Events
Scientific publications
Image bank
About
About BioInvent
Immuno-oncology
Business focus
Board of directors
Management team
Scientific advisory board
Career
Pipeline
Clinical pipeline
BI-1206 / BI-1808
Haematological cancers
Pre-clinical pipeline
TAMs
Tregs
Technology
F.I.R.S.T™
n-CoDeR
Intellectual property
Manufacturing
Partners
Investors
Share price
Financial reports
Presentations
Corporate governance
Subscribe
Media
Press releases
Events
Scientific publications
Image bank
Investors
Welcome to the Investor's section
Financial calendar
25 Feb 2021
Financial statement 2020
29 Apr 2021
Annual General Meeting
